Cetyl myristoleate (CMO) is the common name for cis-9-cetyl myristoleate. CMO was discovered in 1972 by Harry W. Diehl, Ph.D., a researcher at the National Institutes of Health. At the time, Dr. Diehl was responsible for testing anti-inflammatory drugs on lab animals. In order for him to test the drugs, he first had to artificially induce arthritis in the animals by injecting a heat-killed bacterium called Freund’s adjuvant. Dr. Diehl discovered that Swiss albino mice did not get arthritis after injection of Freund’s adjuvant. Eventually, he was able to determine that cetyl myristoleate was the factor present naturally in mice that was responsible for this protection. When CMO was injected into various strains of rats, it offered the same protection against arthritis.1
Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.
For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.
3 Stars Reliable and relatively consistent scientific data showing a substantial health benefit.
2 Stars Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
1 Star For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support.
540 mg per day by mouth for 30 days
Cetyl myristoleate appears to be effective as a joint “lubricant” and anti-inflammatory agent.
Cetyl myristoleate (CMO) has been proposed to act as a joint “lubricant” and anti-inflammatory agent. In a double-blind trial, people with various types of arthritis who had failed to respond to nonsteroidal anti-inflammatory drugs (NSAIDs) received CMO (540 mg per day orally for 30 days), while others received a placebo.2 These people also applied CMO or placebo topically, according to their perceived need. A statistically significant 63.5% of those using CMO improved, compared with only 14.5% of those using placebo.
540 mg daily for 30 days
Cetyl myristoleate may help relieve rheumatoid arthritis symptoms by acting as a joint “lubricant” and anti-inflammatory agent.
Cetyl myristoleate (CMO) has been proposed to act as a joint “lubricant” and anti-inflammatory agent. In a double-blind trial, people with various types of arthritis that had failed to respond to nonsteroidal anti-inflammatory drugs received either CMO (540 mg per day orally for 30 days) or a placebo.3 These people also applied CMO or placebo topically, according to their perceived need. Sixty-four percent of those receiving CMO improved, compared with 14% of those receiving placebo. More research is needed to determine whether CMO has a legitimate place in the treatment options offered RA patients.
Generally, CMO is taken in the amount of 400 to 500 mg daily for 30 days.
Cetyl myristoleate is found in certain animals, including cows, whales, beavers, and mice. As a nutritional supplement it is found in a highly purified, refined form in capsules and tablets. CMO is also available in creams and lotions for topical application.
As CMO is not an essential nutrient, no deficiency state exists.
1. Diehl HW, May EL. Cetyl myristoleate isolated from Swiss albino mice: an apparent protective agent against adjuvant arthritis in rats. J Pharm Sci 1994;83:296-9.
2. Siemandi H. The effect of cis-9-cetyl myristoleate (CMO) and adjunctive therapy on arthritis and auto-immune disease: a randomized trial. Townsend Letter for Doctors and Patients 1997;Aug/Sept:58-63.
3. Siemandi H. The effect of cis-9-cetyl myristoleate (CMO) and adjunctive therapy on arthritis and auto-immune disease: a randomized trial. Townsend Letter for Doctors and Patients 1997;Aug/Sept:58-63.
Last Review: 07-08-2014
Copyright © 2014 Aisle7. All rights reserved. Aisle7.com
The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2015.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.